Research Publications 2009
Articles on CTN studies
January 1, 2009 – December 31, 2009
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodiny M, Cameron DW, Brown ST; OPTIMA Team 1. “Quality of life of patients with advance HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.” J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5): 631-9.
Apuzzo LG, Vaida F, Gallant JE, Ernstrom KB, Little SJ, Routy JP, Collier AC, Conway B, Markowitz MH, Hecht FM, Walker BD, Connick E, Margolick JB. “Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.” J Acquir Immune Defic Syndr. 2009 Mar; 5(3): 267-275.
Harris M, Côté H, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B, Singer J, Montaner J; CTN 177 Study Team. “A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naïve HIV-infected patients.” J Acquir Immune Defic Syndr. 2009 Mar 1; 50(3): 335-337.
Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Cote P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. “Cohort profile: The Canadian HIV-Hepatitis C Co-Infection Cohort Study.”Int J Epidemiol. 2009 Sep 28.
Moodie EEM, Pai NP, Klein MB. “Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.” PLoS ONE 2009; 4(2):e4517.
Moscroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M for the INSIGHT SMART study group. “Interruption of antiretroviral therapy is associated with increased plasma cystain C.” AIDS 2009; 23:71-82.
Articles by CTN Investigators
January 1, 2009 – December 31, 2009
Angel JB, Greaves W, Long J, Ward D, Rodriguez AE, Scevola D, DeJesus E.“Virologic and immunologic activity of PegIntron in HIV disease.” AIDS. 2009 Nov 27; 23(18): 2431-8.
Antiretroviral Therapy Cohort Collaboration. “Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.” Int J Epidemiol. 2009 Dec; 38(6): 1624-33.
Antoniou T, Raboud JM, Kovacs C, Diong C, Brunetta J, Smith G, Halpenny R, Beninger F, Loutfy MR. “Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy.” AIDS Care. 2009 Oct; 21(10): 1247-52.
Breton G, Yassine-Diab B, Cohn L, Boulassel MR, Routy JP, Sékaly RP, Steinman RM.“siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.” J Clin Immunol. 2009 Sep; 29(5): 637-45.
Bogoch I, Walmsley S. “First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach.” Curr Opin HIV AIDS. 2009 Nov; 4(6): 493-8. Review.
Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. “HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.” Nat Med. 2009 Aug; 15(8): 893-900.
Cohen J. “HIV/AIDS research. Surprising AIDS vaccine success praised and pondered.”Science. 2009 Oct 2; 326(5949): 26-7.
Cohen J. “AIDS vaccine research. HIV natural resistance field finally overcomes resistance.” Science. 2009 Dec 11; 326(5959): 1476-7.
de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EL, Coutlée F, HIPVIRG Study Group. “Prevalence, clearance, an incidence of anal human papillomavirus infection in HIV-infected men: The HIPVIRG cohort study.” J Infect Dis. 2009 April 1; 199(7): 965-973.
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. “Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.” Clin Infect Dis. 2009 Nov 15; 49(10): 1582-90.
Faucher S, Crawley AM, Decker W, Sherring A, Bogdanovic D, Ding T, Bergeron M, Angel JB, Sandstrom P. “Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.” PLoS One. 2009 Aug 19; 4(8): e6690.
Fontaine J, Coutlée F, Tremblay C, Routy JP, Poudrier J, Roger M; Montreal Primary HIV Infection and Long?Term Nonprogressor Study Groups. “HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease.” J Infect Dis. 2009 Feb 20. [Epub ahead of print].
Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, Seaberg E, Justman J, Levine AM, Mack WJ, Kovacs A. “Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS).” AIDS Patient Care STDS. 2009 Nov; 23(11): 915-23.
Gathe J, Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. “A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naïve subjects through 48 weeks.” J Acquir Immune Defic Syndr. 2009 Feb 16. [Epub ahead of print].
Grennan T, Walmsley S. “Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.” J Int Assoc Physicians AIDS Care(Chic Ill). 2009 Nov-Dec; 8(6): 354-63. Epub 2009 Oct 23. Review.
Huang KH, Loutfy MR, Boulet S, Toma E, Tsoukas CM, Bernard NF. “Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.” Antivir Ther. 2009; 14(3): 381-92.
Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS. “Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.”J Clin Pharmacol. 2009 Feb; 49(2): 155-61.
Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS. “Epidemiology of treatment failure: a focus on recent trends.” Curr Opin HIV AIDS. 2009 Nov; 4(6): 467-73.
Iannello A, Samarani S, Debbeche O, Ahmad R, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A. “Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells.” J Virol. 2009 Jun; 83(12): 5999-6010.
Iannello A, Samarani S, Debbeche O, Tremblay C, Toma E, Boulassel MR, Routy JP, Ahmad A. “Role of interleukin-18 in the development and pathogenesis of AIDS.” AIDS Rev. 2009 Jul-Sept; 11(3): 115-25.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. “Interleukin-2 therapy in patients with HIV infection.” N Engl J Med. 2009 Oct 15; 361(16): 1548-59.
Jürgens R, Cohen J, Cameron E, Burris S, Clayton M, Elliott R, Pearshouse R, Gathumbi A, Cupido D. “Ten reasons to oppose the criminalization of HIV exposure or transmission.” Reprod Health Matters. 2009 Nov; 17(34): 163-72.
Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, Mason RD, Mohamed MR, MacDonald KS, Kovacs C, Ostrowski MA. “Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.” J Virol. 2009 Sep; 83(17): 8722-32.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. “Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.” AIDS. 2009 Nov 13; 23(17): 2289-300.
Kiberd MB, Cooper C, Slaunwhite JM, Halperin B, Haase D, McNeil SA. “Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.” Can J Infect Dis Med Microbiol. 2009; 20(4): 124-129.
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD; NA-ACCORD Investigators. “Effect of early versus deferred antiretroviral therapy for HIV on survival.” N Engl J Med. 2009 Apr 30; 360(18): 1815-26.
Lee PI, Ciccone EJ, Read SW, Asher A, Pitts R, Douek DC, Brenchley JM, Sereti I.“Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia.” J Infect Dis. 2009 Jun 1; 199(11): 1664-70.
Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner J. “The combined effect of modern highly active antiretroviral therapy regimens and adherance on mortality over time.” J Acquir Immune Defic Syndr. 2009 Feb 13. [Epub ahead of print]
Lima V, Harrigan R, Montaner J. “Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the pagman assay in comparison to the amplicor assay.” J Acquir Immune Defic Syndr. 2009 Feb 25. [Epub ahead of print]
Loutfy MR, Hart TA, Mohammed SS, Su D, Ralph ED, Walmsley SL, Soje LC, Muchenje M, Rachlis AR, Smaill FM, Angel JB, Raboud JM, Silverman MS, Tharao WE, Gough K, Yudin MH; Ontario HIV Fertility Research Team. “Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study.” PLoS One. 2009 Dec 7; 4(12): e7925.
Ma W, Mishra S, Gajanayaka N, Angel JB, Kumar A. “HIV-1 nef inhibits lipopolsaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappa B in human monocytic cells.” J Biol Chem. 2009 Mar 20; 284(12): 7578-75.
Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team. “Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.” J Acquir Immune Defic Syndr. 2009 Nov 1; 52(3): 350-6.
Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. “Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).” J Int AIDS Soc. 2009 Jun 30; 12(1): 11.
Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.“Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.” J Antimicrob Chemother. 2009 Aug; 64(2): 398-410. Epub 2009 Jun 10.
Money D. “H1N1 in pregnant women: A challenge overlooked?” J Obstet Gynaecol Can. Invited Editorial. 2009 Nov.
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration. “Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.” J Acquir Immune Defic Syndr. 2009 Nov 1; 52(3): 357-63.
Moscroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M for the INSIGHT SMART study group. “Interruption of antiretroviral therapy is associated with increased plasma cystain C.” AIDS 2009; 23: 71-82.
Ndongala ML, Perestz Y, Boulet S, Doroudchi M, Yassine-Diab B, Boulassel MR, Rouleau D, Tremblay C, Leblanc R, Routy JP, Sékaly RP, Bernard NF. “HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load.” Clin Immunol.2009 Jan 7.
Nosyk B, Sun H, Bansback N, Guh DP, Li X, Barnett P, Bayoumi A, Griffin S, Joyce V, Holodiny M, Owens DK, Anis AH. “The concurrent validity and responsiveness of the health utilities (HUI 3) among patients with advanced HIV/AIDS.” Qual Life Res. 2009 Sept; 18(7): 815-24.
Pai NP, Joshi R, Moodie EE, Taksande B, Kalantri SP, Pai M, Tulsky JP, Reingold A.“Profile of adults seeking voluntary HIV testing and counseling in rural Central India: results from a hospital-based study”. AIDS Care 2009 March; 21(3): 294 300.
Pai NP, Klein MB. “Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges.” Women’s Health 2009; 5(1), 55-62.
Perreault M, Mousseau M, Laurier C, Rabouin D, Desbiens S, Côté P, Rouleau D, Lahaie C, Charron MA, Carbonneau MJ. “Treatment of HIV marginalized patients: an approach to documenting medical and psychosocial appointments of patients with problematic drug use.” Can J Public Health. 2009 Nov-Dec; 100(6): 459-62.
Potter M, Klein MB. “Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B.” HIV Therapy. 2009, 3: 189-207.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. “Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.” J Infect Dis. 2009 Sep 15; 200(6): 973-83.
Sheth PM, Kovacs C, Kemal KS, Jones RB, Raboud JM, Pilon R, la Porte C, Ostrowski M, Loutfy M, Burger H, Weiser B, Kaul R; Toronto Mucosal Immunology Group.“Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.” AIDS.2009 Sep 24; 23(15): 2050-4.
Sturtevant D, Preiksaitis J, Singh A, Houston S, Gill J, Predy G, Fisher D, Senthilselvan A, Manfreda J, Boffa J, Long R. “The feasibility of using an ‘opt-out’ approach to achieve universal HIV testing of tuberculosis patients in Alberta.” Can J Public Health. 2009 Mar-Apr; 100(2): 116-20.
Tan D, Asztalos E, Douglas D, Read S, Bitnun A. “Congenital transmission of human immunodeficiency virus, cytomegalovirus, and toxoplasmosis in a premature infant.”Pediatr Infect Dis J. 2009 Dec; 28(12): 1129-31.
Tan D, Kaul R, Walmsley S. “Left out but not forgotten: Should closer attention be paid to co-infection with herpes simplex virus type 1 and HIV?” Can J Infect Dis Med Microbiol.2009; 20: e1-e7.
Tcherepanova I, Starr A, Lackford B, Adams MD, Routy JP, Boulassel MR, Calderhead D, Healey D, Nicolette C. “The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.” PLoS One. 2009 Jun 10; 4(6): e5853.
Wainberg MA. “New findings on blockage of HIV-1 RNase H activity.” AIDS. 2009 Jan 14;23(2): 223-4.
Wainberg MA, Martinez-Cajas JL. “Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease.” Infect Disord Drug Targets. 2009 Apr; 9(2): 172-90. Review.
Walmsley SL, Squires K, Weiss L, Easterbrook P, Orani A, Kraft M, Scherer J.“Multidrug-experienced HIV-1 infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men”. AIDS. 2009 Jan 28; 23(3): 429-31.
When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. “Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.” Lancet. 2009 Apr 18; 373(9672): 1352-63.
Zuniga JM, Whiteside A, Ghaziani A, Bartlett JG (editors). “A decade of HAART–the development and global impact of highly active antiretroviral therapy.” Eur J Public Health. 2009 Mar 5.
January 1, 2009 – April 1, 2009
16th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2009, Montréal
Duprez D, and INSIGHT/SMART Group. “High-density lipoprotein particles but not low-density lipoprotein particles predict cardiovascular disease events in HIV patients: strategies for management of ART study.” Oral abstract 149.
Levy Y, and the SILCAAT Science Committee. “Effect of interleukin 2-on clinical outcomes in patients with CD4+ cell count 50 to 299/mm3: primary results of the SILCAAT study.” Oral abstract 90bLB.
Losso M, Abrams D, and INSIGHT ESPRIT Study Group. “Effect of interleukin 2-on clinical outcomes in patients with a CD4+ cell count of 300/mm3: primary results of the ESPRIT study.” Oral abstract 90Alb.
Baker J, Duprez D, Rapkin J, Grimm R, Neaton J, Henry K. “Untreated HIV infection is associated with impaired arterial elasticity.” Poster 725.
Rodger A, Fox Z, Lundgren J, Kuller L, Boesecke C, Gey D, Skoutelis A, Goetz M, Philips A, for the INSIGHT SMART study group. “Does activation of inflammatory and coagulation pathways independently predict the development of opportunistic disease in patients with HIV infection?” Poster 733.
Peters L, for the INSIGHT SMART study group. “Interruption of ART changes in hyaluronic acid as marker of liver fibrosis progression in strategies for management of ART viral hepatitis-co-infected participants and matched controls.” Poster 858.
Neuhaus J, Jacobs D, and the INSIGHT SMART, MESA, and CARDIA study groups.“Markers of inflammation, coagulation, and renal function in HIV-infected adults in the strategies for management of ART study and in 2 large population-based studies, coronary artery risk development in young adults and multi-ethnic study of atherosclerosis.” Poster 740.
Anis A, Sun H, Nosyk B, Guh D, Bansback N, Singer J, Holodniy M, Brown ST, Kyriakides T, Cameron DW. “Predicting death, AIDS and serious adverse events in the
OPTIMA trial.” Poster 135.
Feng DY, Goupil C, Mathieu J, Delisle M,Chiasson JC, Dagenais C, Gagné C, Swidzinski M, Boulassel MR for the CTN 239 investigators, Routy JP for the CTN-239 Study Investigators. ”A nursing perspective of apheresis procedures performed in HIV-infected subjects receiving a monocytes-derived dendritic cell-based immunotherapy.” Poster 162.
Gill J. “The challenge and costs in HIV of late presentations and disconnections from care.” Gilead Lunch Symposium.
Harris M, Hull M, Ochoa P, Toulson A, Montaner J. “Immediate vs. deferred substitution of dual boosted protese inhibitors (PIS) with darunavir/ritonavir (DRV/R).” Oral presentation.
Harris M, Hull M, Ochoa P, Toulson A, Montaner J. “Immediate vs. deferred substitution of dual boosted protease inhibitors (PIs) with darunavir/ritonavir (DRV/r).” Oral presentation.
Hogg R; Palmer AK, Milan D, Yip B, Klein M, Loutfy M, Raboud J, Machouf N, Rourke SB, Taylor D, Tsoukas C, Smieja M, Cooper C, Montaner J, CANOC Collaboration.“Canada’s National HIV Cohort Study: The Canadian Observational Cohort Collaboration (CANOC) (E).” Poster 226.
Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron W, Sculpher M, Youle M, Anis AH, Owens DK. “Impact of treatment interruptions and mega-ART on health-related quality of life in the OPTIMA trial.” Canadian Journal of Infectious Diseases. Poster 134.
Kaida, A, Forrest J, Money D, Burdge D, Forbes J, Fernandes K, Milan D, Hogg R.“Antiretroviral adherence during pregnancy and postpartumamong HIV-positive women enrolled in the Drug Treatment Program in British Columbia, Canada.” Oral presentation.
Kamya PN, Boulet S, Cecile T, Bernard N, Investigators of the Montreal Slow Progressor Cohort. “Assessment of the functional potential of NK cells and NK cell subsets in HIV infected slow progressors carrying different KIR/HLA genotypes.” Oral presentation.
Keller M, Gill J, Tan D, Walmsley S, Lalonde RG, Klein M. “HIV-1 viral subtype affects CD4+ T-cell decline and clinical outcome in antiretroviral naïve patients receiving health care in Canada.” Oral presentation.
Loutfy, M, Genebat M, Moore DM, Chan K, Raboud J, Shen A, Li M, Klein M, Cooper C, Machouf N, Rourke SB, Tsoukas C, Smieja M, Montaner J, Hogg R, CANOC Collaboration. “Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4count ? 200 cells/mm3 after two years of combination antiretroviral therapy (cART).” Poster 208.
Machouf N, Ding E,. Lima VD, Palmer AK, Loutfy M, Klein M, Montaner J, Raboud J, Rachlis A, Smieja M, Tsoukas C, Cooper C, Rourke SB, Hogg R, CANOC Collaboration. “Time to virologic suppression among HIV-infected individuals on HAART in Canada (E).” Poster 209.
Mtambo A, Moore D, Chan K, Harrigan RP, Yip B, Montane J, Lima VD, Hogg R.“Treatment limitations imposed by antiretroviral drug resistance mutations: a comparison of initial regimenscontaining boosted PIs with those containing NNRTIs.” Oral presentation.
Moore D, Barrios R, Zhang W, Lepik KJ, Yip B, Shen A, Hogg R, Lima V, Bondi G, Montaner J. “Dyslipidemia associated with use of specific antiretroviral drugs in British Columbia, Canada.” Poster 160.
Raboud J, Bayoumi A, Su D, Loutfy M,Machouf N, Smieja M, Rachlis A, Tsoukas C, Smieja M, Rourke SB, Cooper C, Klein M, Montaner J, Hogg RS, CANOC Collaboration. “Regional differences in rates of viral load testing in Canada CANOC collaboration.” Poster 211.
Routy, JP. “HAART in action: Case discussions on current guidelines and beyond.” Bristol-Myers Squibb Lunch Symposium.
Routy JP, Vezina S, Tremblay C, Baril JG, Loutfy M; Gill J, Renu J, Nicolette C, Sekaly RP, Boulassel MR for the CTN 239 investigators. “Safety and feasibility of a multicentre phase II trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation (CTN 239).” Poster 163.
Singer J, Kyriakides T, Babiker A, Anis A, Brown S, Holodniy M, Angus B, Schechter MT, Cameron W. “Clinical outcomes from OPTIMA: A pragmatic randomised control trial of antiretroviral treatment strategies in advanced multi-drug resistant HIV infection.” Canadian Journal of Infectious Diseases. Oral presentation.
Singer J, Lapointe N, Money D, Alimenti A, Forbes J, Samson L, Bitnun A, Ayers D.“Perinatal HIV Transmission and maternal viral load: data from the Canadian Perinatal HIV Surveillance Program.” Oral presentation.
Singer J, Tremblay C, Rouleau D, Angel J, Trottier B, Montaner J, Baril JG, Trottier S, Bichel D, Routy JP. “RCT of valproic acid to purge HIV from resting CD4+ memory cells: Design, analysis and Study Progress.” Poster 144.
Singhal N, Su Y, Singer J, Cameron W. “The effect of mixed carotenoids supplementation on CD4 T lymphocyte count in HIV/AIDS.” Oral presentation.
Tan DH, Ota K, 2, Fisman D. “The impact of tenofovir-based HIV pre-exposure prophylaxison life expectancy and quality-adjusted life expectancy: A markov cohort model.” Oral presentation.
Anis A, Cameron DW, Sun H, Guh DP, Nosyk B, Bansback N, Singer J, Holodniy M, Brown ST, Kyriakides TC for the OPTIMA Study Group. “The effect of treatment on immune reconstitution of multi-drug resistant HIV/AIDS patients.” Poster.
Anis A, Barnett PG, Nosyk B, Chow A, Sun H, Sculpher MJ, Singer J. “A multinational comparison of the costs of treatment of late-stage HIV/AIDS in the OPTIMA Trial.” Poster.
Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Spira B, Xu H, Brenner BG, Wainberg MA. “Mechanisms of differential resistance development in subtype-B and C HIV-1: a study of the K65R, D67N, K103N, V106M and M184V drug resistance mutations.”
Durand M, Sheehy O, Baril jg, Lelorier J, Tremblay C, for the GRUCHUM (Groupe de Recherche de l’UHRESS du CHUM). “Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec’s public health insurance database (QPHID).” B39 Cardiovascular disease and other end organ damage.
Lisovsky I, Martinez Cajas JL, Oliveira M, Moisi D, Golubkov O, Wainberg MA.“Phenotypic Susceptibility and Drug Resistance Profile of HIV-1 B, C and AG Clones Selected with Atazanavir, Lopinavir and Nelfinavir.”
Routy JP. “Treatments to mobilize the reservoirs”. Determinants of viral reservoirs: Prospects for eradication. Oral presentation.
Routy JP, Jain R, Boulassel MR, Nicolette C, Finke L, Jacobson J. “Assessing risk of a 12-week antiretroviral therapy discontinuation as a read out of viral control in immune-based therapy (AGS-004-001 study).” Poster presentation.
Routy JP, Vezina S, Tremblay C, Angel J, Baril JG, Loufty M, Gill J, Jain R, Nicolette C, Sekaly R, Boulassel MR, and the, Canadian HIV Trials network CIHR/CTN 239 investigators. “Safety and feasibility of a multicentre phase 2 trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation.” B42.
Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. “Genotypic, phenotypic and virtual phenotypic resistance patterns for tipranavir (TPV) and darunavir (DRV): An independent analysis of a Quebec HIV-1 cohort highly resistant to all other protease inhibitors.”
Wainberg MA, Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG.“Mechanistic Analysis of the Preference for the K65R Multi-Resistance Nucleoside Mutation in Subtype C Viruses.”